Because of the accumulating evidence that PIK3CA mutation/PTEN expression status predicts colon carcinoma response to the EGFR inhibitor cetuximab [72-74], we are currently investigating whether the combination of cetuximab with metformin could be an effective therapeutic option in PIK3CA-mutated colon cancer. This evidence concerns the gene PTEN and colonic neoplasm.